This update to SPC follows EU wide review resulting in recommendations that all patients should be screened for hepatitis B before starting treatment for chronic hepatitis C with direct-acting antiviral interferon-free regimens. In addition, it is advised that as patients who are co-infected with hepatitis B and C viruses are at risk of hepatitis B reactivation, they should be monitored and managed according to current clinical guidelines.